Ian Mitchell McElree

Ian Mitchell McElree

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Journal of Urology
Verified
Journal Article
Open access
IMIan Mitchell McElree
Ian Mitchell McElree
RSRyan L. Steinberg
Ryan L. Steinberg
AMAlex C. Martin
Alex C. Martin
JRJordan Richards
Jordan Richards
SMSarah L. Mott
Sarah L. Mott
VPVignesh T. Packiam
Vignesh T. Packiam
Purpose:Bacillus Calmette-Guérin (BCG) is currently recommended as adjuvant therapy following complete transurethral resection of bladder tumor for high-risk nonmuscle-invasive bladder cancer (NMIB...

28 November 2022 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
PCPhani T. Chevuru
Phani T. Chevuru
IMIan Mitchell McElree
Ian Mitchell McElree
SMSarah L. Mott
Sarah L. Mott
RSRyan L. Steinberg
Ryan L. Steinberg
MOMichael A. O'DOnnell
Michael A. O'DOnnell
VPVignesh T Packiam
Vignesh T Packiam

25 August 2024 in BJU International
Verified
Journal Article
Open access
JTJacob I. Taylor
Jacob I. Taylor
AKAshish M. Kamat
Ashish M. Kamat
MOMichael A. O'DOnnell
Michael A. O'DOnnell
DADrupad Annapureddy
Drupad Annapureddy
JHJeffrey Howard
Jeffrey Howard
YLYair Lotan
Yair Lotan
Objective: To quantify the oncological risks of bladder‐sparing therapy (BST) in patients with Bacillus Calmette–Guérin (BCG)‐unresponsive non‐muscle‐invasive bladder cancer (NMIBC) compared to upfront radical cystectomy (RC). Patients and Methods: Pre‐specified data elements were collected from retrospective cohorts of patients with BCG‐unresponsive NMIBC from 10 international sites. After Institutional Review Board approval, patients were included if they had BCG‐unresponsive NMIBC meeting United States Food and Drug Administration criteria. Oncological outcomes were collected following upfront RC or BST. BST regimens included re‐resection or surveillance only, repeat BCG, intravesical chemotherapy, systemic immunotherapy, and clinical trials. Results: Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months. There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups. In the BST group, high‐grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively. RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC ( P = 0.030). Conclusion: In a selected cohort of patients, initial BST offers comparable survival outcomes to upfront RC in the intermediate term. Rates of recurrence and progression increase over time especially in patients treated with additional lines of BST.

1 November 2022 in Journal of Urology
Verified
Journal Article
Closed access
IMIan Mitchell McElree
Ian Mitchell McElree
VPVignesh T. Packiam
Vignesh T. Packiam
RSRyan L. Steinberg
Ryan L. Steinberg
SMSarah L. Mott
Sarah L. Mott
PGPaul T. Gellhaus
Paul T. Gellhaus
MOMichael A. O'DOnnell
Michael A. O'DOnnell
Introduction:Intravesical gemcitabine-docetaxel (Gem/Doce) has emerged as an efficacious and well-tolerated salvage therapy for NMIBC. However, further rescue therapies are needed for subsequent re...

11 July 2023 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
IMIan Mitchell McElree
Ian Mitchell McElree
JOJoanna Orzel
Joanna Orzel
RSReid Stubbee
Reid Stubbee
RSRyan L. Steinberg
Ryan L. Steinberg
SMSarah L. Mott
Sarah L. Mott
VPVignesh T Packiam
Vignesh T Packiam

26 October 2023 in BJU International
Verified
Journal Article
Open access
IMIan Mitchell McElree
Ian Mitchell McElree
SMSarah L. Mott
Sarah L. Mott
MOMichael A. O'DOnnell
Michael A. O'DOnnell
VPVignesh T. Packiam
Vignesh T. Packiam